Suppr
超能文献

Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review.

作者信息

Cipriano Élia, Magalhães Helena, Tavares Catarina, Pinto João, Cirnes Luís, Estevinho Fernanda

机构信息

Department of Medical Oncology.

Department of Radiology.

出版信息

Porto Biomed J. 2021 Feb 11;6(1):e124. doi: 10.1097/j.pbj.0000000000000124. eCollection 2021 Jan-Feb.

DOI:10.1097/j.pbj.0000000000000124

PMID:33884320

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8055486/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/8055486/f104519991dd/pj9-6-e124-g001.jpg

相似文献

Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review.

Porto Biomed J. 2021 Feb 11;6(1):e124. doi: 10.1097/j.pbj.0000000000000124. eCollection 2021 Jan-Feb.

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.

PLoS One. 2016 Aug 12;11(8):e0161081. doi: 10.1371/journal.pone.0161081. eCollection 2016.

Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.

Lung Cancer. 2014 Nov;86(2):291-5. doi: 10.1016/j.lungcan.2014.09.011. Epub 2014 Sep 28.

Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.

Cancer Cytopathol. 2013 Sep;121(9):500-7. doi: 10.1002/cncy.21288. Epub 2013 Mar 12.

Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.

Cancer. 2012 Nov 15;118(22):5588-94. doi: 10.1002/cncr.27603. Epub 2012 May 8.

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.

Diagn Pathol. 2020 May 6;15(1):42. doi: 10.1186/s13000-020-00969-1.

[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].

Rev Mal Respir. 2017 May;34(5):576-580. doi: 10.1016/j.rmr.2016.08.002. Epub 2016 Sep 17.

Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.

Lung Cancer. 2013 Mar;79(3):242-7. doi: 10.1016/j.lungcan.2012.11.021. Epub 2012 Dec 20.

Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.

Pathol Res Pract. 2018 Dec;214(12):2103-2105. doi: 10.1016/j.prp.2018.09.028. Epub 2018 Oct 1.

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.

Cureus. 2016 Feb 26;8(2):e513. doi: 10.7759/cureus.513.

引用本文的文献

Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced -Rearranged NSCLC.

Int J Mol Sci. 2025 Jun 21;26(13):5969. doi: 10.3390/ijms26135969.

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib.

Cureus. 2023 Nov 1;15(11):e48122. doi: 10.7759/cureus.48122. eCollection 2023 Nov.

本文引用的文献

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Clin Transl Oncol. 2020 Jul;22(7):989-1003. doi: 10.1007/s12094-019-02218-4. Epub 2019 Oct 9.

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.

Nat Rev Cancer. 2019 Sep;19(9):495-509. doi: 10.1038/s41568-019-0179-8. Epub 2019 Aug 12.

Mutational profile of non-small cell lung cancer patients: Use of next-generation sequencing.

Pulmonology. 2020 Jan-Feb;26(1):50-53. doi: 10.1016/j.pulmoe.2019.05.003. Epub 2019 Jun 2.

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.

Target Oncol. 2019 Apr;14(2):169-178. doi: 10.1007/s11523-019-00628-6.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:726-739. doi: 10.1200/EDBK_201331.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

J Mol Diagn. 2018 Mar;20(2):129-159. doi: 10.1016/j.jmoldx.2017.11.004. Epub 2018 Jan 23.

Concomitant rearrangement and mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Oncotarget. 2017 Apr 26;8(35):59889-59900. doi: 10.18632/oncotarget.17431. eCollection 2017 Aug 29.

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译